Excellence List丨JYSS BIO won the " 2021 Best IVD and Life Science Enterprise Award"

On April 2, 2022, Haoyue Capital , an industrial investment bank focusing on China's medical and healthcare, officially released the "2022 6th Medical and Health Investment Excellence List". JYSS BIO won the " 2021 IVD and Life Science Best Enterprise Award ".

As an annual authoritative list highly recognized by the peers, since its first release in 2017, the Medical and Health Investment Bonus List has always adhered to the principles of fairness, impartiality, objectivity and neutrality. In meanwhile, the Excellence List also gave awards to outstanding medical and healthcare companies in different fields such as biopharmaceuticals, innovative medical devices, in-vitro diagnostics, medical services, and smart healthcare, aiming to create a truly credible and influential investment list, set a new benchmark for the development of the industry and create new opportunities for investment cooperation. In recent years, based on it’s own innovation and continuous R&D JYSS BIO has built an advanced platform integrated with research and manufacturing on bioprocessing systems and consumables aiming to create a full-process solution that runs through the upstream and downstream bioprocesses.

JYSS BIO was established in 2014. As the first high-tech enterprise in China to realize the localization of disposable bioreactor and disposable consumables technology, JYSS BIO has been deeply involved in biotechnology industry in recent years and insists on independent innovation. The company's products have been widely applied in vaccines, gene and cell therapy, antibody drugs and other fields and have been recognized by more and more customers.

In September 2020, JYSS BIO officially delivered the first batch of contract orders for CanSino’s new vaccine——adenovirus vector vaccine, and was rated as a “Supplier with Outstanding Contribution to the Fight against COVID-19” by CanSino .

In September 2021, a new plant was settled in Blue Bay, Lingang New Area of Shanghai Free Trade Zone.

In December 2021, the construction of a factory base of 27,000 m² in Huzhou has been launched.

In 2021, JYSS BIO successfully completed the A and B rounds of financing, and completed the B+ round of financing in early 2022.

In November 2021, JYSS BIO was listed on the "2021 Bio-Industry Annual Climbing List" of BioValley, and was selected as "Top 5 Biotechnology Equipment Suppliers of the Year"

Independent research and development, continuous innovation

In terms of scientific and technical achievements, the company took scientific and technical innovation as the core driving force to promote the high-quality development of the enterprise. It actively builds an innovation platform, and has mastered a number of key core technologies with independent intellectual property rights. Up to now, the company has obtained 42 patents, including 3 worldwide patents and 39 national patents.

Create platform to generate the whole process solution from upstream to downstream

As a pioneer in the field of biotechnology, JYSS BIO has always adhered to the values and development concepts of "focus, refinement, honesty, and perseverance". In the future, JYSS BIO will further expand the fields of the bioprocessing industry and provide high-quality products and solutions for more pharmaceutical companies..